*As corresponding author:
J Chen, NA Kaya, Y Zhang, RI Kendarsari, et al V Chew et al PKH Chow. A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and ‘bad apple’ effect on clinical trajectory. J Hepatology, 2024. https://doi.org/10.1016/j.jhep.2024.05.017.
BC Narmada, A Khakpoor, N Shirgaonkar et al V Chew et al SG Lim and R DasGupta. Single cell landscape of functionally cured Chronic Hepatitis B patients reveals activation of innate and an altered CD4-CTL-driven adaptive immunity. J Hepatology, 2024.
https://doi.org/10.1016/j.jhep.2024.02.017.
HD Lee, SY Jung, et al V Chew et al CH Yoo. Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial. Nature Medicine, 2024. https://doi.org/10.1038/s41591-024-02824-y.
S Ma & V Chew*. Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology, 2023; 10.1097.
V Chew*. Unveiling the hidden battlefield: dissecting the invasive zone in liver cancer. Cell Research, 2023; 33, 651–652.
MJY Reolo, M Otsuka, et al V Chew*. CD38 marks the exhausted CD8+ tissue-resident memory T cells in hepatocellular carcinoma. Front.Immunol, 2023; 14, 1182016.
YH Lee, S Chuah, et al V Chew*. IFNγ− IL-17+ CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinoma. Cancer Letters, 2023; 215977.
S Chuah, J Lee, Y Song, et al D Tai, V Chew*. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. J Hepatology, 2022.
P Nguyen, M Wasser et al. V Chew*. Trajectory of immune evasion and cancer progression in hepatocellular carcinoma. Nature Com, 2022.
S Suthen, CJ Lim, P Nguyen et al. V Chew*. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in hepatocellular carcinoma. Hepatology, 2022.
S Chuah and V Chew*. Immune implication of an autophagy-related prognostic signature in uveal melanoma. Bioscience reports, 2021. Vol 41 (8), BSR20211098.
P Nguyen, S Ma et al P Chow, W Zhai and V Chew*. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nature Com, 2021; 12, 227.
CJ Lim et al. V Chew*. Immunological hallmarks for clinical response to BCG in bladder cancer. Front. Immunol, 2021. https://doi.org/10.3389/fimmu.2020.615091.
CJ Lim and V Chew*. Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma. Semin Liver Dis, 2020.
YH Lee, D Tai, C Yip, SP Choo and V Chew*. Combinational immunotherapy for Hepatocellular carcinoma (HCC): Radiotherapy, immune checkpoint blockade and beyond. Front. Immunol, 2020; Sep 30;11:568759. doi: 10.3389/fimmu.2020.568759.
S Chuah and V Chew*. High-dimensional immune-profiling in cancer- implications for immunotherapy. Journal for ImmunoTherapy of Cancer (JITC), 2020;8:e000363. doi: 10.1136/jitc-2019-000363.
D Tai, SP Choo and V Chew*. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019; 11(12), 1926.
CJ Lim, YH Lee, et al. V Chew*. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut, 2019; May;68(5):916-927.
V Chew*, YH Lee, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut, 2019; 68(2): 335-346.
V Chew*, L Lai, L Pan, CJ Lim, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proceedings of the National Academy of Sciences, 2017; 114(29): E5900-E5909.
M Garnelo, A Tan, et al. V Chew*. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut, 2017; 66(2): 342-351.
